Proactiveinvestors recommends

Full profile here
Pdf

NeoStem's Progentior Cell Therapy boosts business through new contract additions

3rd May 2011, 12:32 pm by Deborah Sterescu
NeoStem's Progentior Cell Therapy boosts business through new contract additions

New York-based NeoStem (AMEX:NBS) said Tuesday that Progenitor Cell Therapy, the US cell therapy company it acquired in January, has expanded the business through new contracts and extensions.

Since starting out as a provider of adult stem cell collection and storage services, New York-based NeoStem has since branched out into cell therapeutics, focused on using stem cells to help cure disease.

In January, the company acquired Progenitor, which has cell therapy manufacturing facilities, as well as processing and storage facilities for stem cells collected from the umbilical cord at birth, located on the east and west coast of the US. Progenitor has performed over 30,000 cell therapy procedures and has processed and stored over 18,000 cell therapy products.

"PCT has unique insight into the growth of the cell therapy industry as we help our clients advance their product candidates from early stage to late stage clinical trials," said NeoStem CEO, Dr. Robin Smith.

"We continue to see PCT as an enabling transaction that provides NeoStem with core expertise in cell-based manufacturing, enhanced regulatory affairs capabilities and clinical development."

No terms of the new contracts or extensions were disclosed.

Currently, NeoStem is working with Progenitor on the development of its VSEL platform, which uses very small embryonic-like stem cells for therapeutic use, as well as Athelos Corp's T-cell treatment for a range of auto-immune diseases. NeoStem owns 80% of Athelos through Progenitor.

"It is my strong belief that NeoStem will become a major provider of cell-based medicines in the future and we will continue to plan for growth in this area and position ourselves to fund such activities through a variety of means that could include the calling of our outstanding warrants, divestiture of assets or acquisition related or other financing," added Dr. Smith.

NeoStem also has operations in China, currently building a cell-based manufacturing lab in Beijing, as well as commercializing its cell therapies through a network of hospitals in the region. The US stem cell company also owns a majority-interest in Chinese generic antibiotics company Suzhou Erye.

No investment advice


Proactive Investors North America Inc, trades as "Proactiveinvestors USA & Canada".


You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.


You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.


From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.


You understand that we may be providing advertising and/or marketing services to companies mentioned on the site. A full list of companies that are paying for services from us, or our affiliated companies in the UK and Australia can be viewed here